Publications by authors named "Minjuan Hu"

Claim this Profile
C
Coinhibition of the MEK/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancer.
Jun Lu, Minjuan Hu, Yikai Zhao, Tianqing Chu, Wei Zhang, Liang Hu, Chunlei Shi, Huimin Wang, Liang Zhu, Hua Zhong, Baohui Han

Signal Transduct Target Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclosporine successfully treats steroid-resistant checkpoint inhibitor-related pneumonitis: a case report.
Jiaxi Deng, Wenhui Guan, Minjuan Hu, Haiyi Deng, Wenwei Mo

BMC Pulm Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic impact of severe grade immune checkpoint inhibitor related pneumonitis in non-small cell lung cancer patients.
Ni Sun, Ru Li, Haiyi Deng, Qingyang Li, Jiaxi Deng, Yue Zhu, Wenhui Guan, Minjuan Hu

Front Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PEG2000-PLA-based nanoscale polymeric micelles reduce paclitaxel-related toxicity in beagle dogs.
Jun Lu, Bo Han, Bo Zhang, Benkun Zou, Minjuan Hu, Shuyuan Wang, Tianqing Chu, Baohui Han, Hua Zhong

J Control Release· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extracellular vesicle long RNA markers of early-stage lung adenocarcinoma.
Yanwei Zhang, Wei Liu, Hongdao Zhang, Beibei Sun, Tianxiang Chen, Minjuan Hu, Baohui Han

Int J Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case report: Spontaneous remission in lung carcinoma with a late relapse after adjuvant immunotherapy: Exceptional tumor micro-environment.
Yan Chen, Wenhui Guan, Changhao Zhong, Jiaxi Deng, Minjuan Hu

Front Immunol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.
Yanan Wang, Ya Chen, Zhengyu Yang, Fangfei Qian, Minjuan Hu, Baohui Han

Ann Surg Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined large cell neuroendocrine carcinoma: clinical characteristics, prognosis and postoperative management.
Zhengyu Yang, Yanan Wang, Ya Chen, Fangfei Qian, Yanwei Zhang, Minjuan Hu, Baohui Han

Eur J Cardiothorac Surg· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells.
Jun Lu, Wei Xu, Jie Qian, Shuyuan Wang, Bo Zhang, Minjuan Hu, Baohui Han

BMC Med Genomics· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer.
Zhengyu Yang, Ya Chen, Yanan Wang, Minjuan Hu, Fangfei Qian, Baohui Han

Front Immunol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.
Wensheng Zhou, Zhichao Liu, Yanan Wang, Yanwei Zhang, Fangfei Qian, Huimin Wang, Minjuan Hu, Baohui Han

Cancer Med· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: A retrospective observational study.
Ya Chen, Yanan Wang, Zhengyu Yang, Minjuan Hu, Jun Lu, Shuyuan Wang, Baohui Han

Thorac Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update.
Jun Lu, Tianqing Chu, Hongyu Liu, Minjuan Hu, Yuqing Lou, Huimin Wang, Hua Zhong, Baohui Han

Chin J Cancer Res· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DUBR suppresses migration and invasion of human lung adenocarcinoma cells via ZBTB11-mediated inhibition of oxidative phosphorylation.
Wei Nie, Min-Juan Hu, Qin Zhang, Jun Lu, Fang-Fei Qian, Fang Hu, Chang-Hui Li, Shu-Hui Cao, Bao-Hui Han

Acta Pharmacol Sin· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer.
Jun Lu, Runbo Zhong, Yuqing Lou, Minjuan Hu, Zhengyu Yang, Huimin Wang, Baohui Han

Front Immunol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among -Negative NSCLC Patients.
Jun Lu, Yanwei Zhang, Yuqing Lou, Bo Yan, Benkun Zou, Minjuan Hu, Huimin Wang, Baohui Han

Front Genet· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Study of Pulmonary Combined Large-Cell Neuroendocrine Carcinoma and Combined Small-Cell Carcinoma in Surgically Resected High-Grade Neuroendocrine Tumors of the Lung.
Yanan Wang, Fangfei Qian, Ya Chen, Zhengyu Yang, Minjuan Hu, Baohui Han

Front Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations.
Zhengyu Yang, Ya Chen, Yanan Wang, Shuyuan Wang, Minjuan Hu, Baohui Han

Front Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study.
Ya Chen, Yanan Wang, Zhengyu Yang, Minjuan Hu, Yanwei Zhang, Baohui Han

Front Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical significance of visceral pleural and lymphovascular invasion in surgically resected adenosquamous lung cancer.
Yanan Wang, Fangfei Qian, Minjuan Hu, Ya Chen, Zhengyu Yang, Baohui Han

Eur J Cardiothorac Surg· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab Plus Chemotherapy or Anlotinib Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC.
Ya Chen, Zhengyu Yang, Yanan Wang, Minjuan Hu, Bo Zhang, Baohui Han

Front Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PlGF knockdown attenuates hypoxia-induced stimulation of cell proliferation and glycolysis of lung adenocarcinoma through inhibiting Wnt/β-catenin pathway.
Wei Zhang, Yanwei Zhang, Wensheng Zhou, Fangfei Qian, Minjuan Hu, Baohui Han

Cancer Cell Int· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring or mutation.
Wei Nie, Lu Gan, Xin Wang, Kai Gu, Fang-Fei Qian, Min-Juan Hu, Shu-Hui Cao, Shu-Yuan Wang, Chang-Hui Li, Hua Zhong, Bao-Hui Han

Oncoimmunology· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis.
Ya Chen, Shuyuan Wang, Bo Zhang, Yiming Zhao, Lele Zhang, Minjuan Hu, Baohui Han

Target Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients.
Yanwei Zhang, Beibei Sun, Minjuan Hu, Yuqing Lou, Jun Lu, Huimin Wang, Tianqing Chu, Baohui Han

Front Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis